These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Cardiac arrhythmias (III). The classification of anti-arrhythmia drugs in the 90s: a focus for the cardiologist]. Tamargo J; Valenzuela C; Delpón E Rev Esp Cardiol; 1993 Mar; 46(3):183-94. PubMed ID: 8387683 [No Abstract] [Full Text] [Related]
3. [General principles for choosing an anti-arrhythmia preparation and the treatment procedure in cardiac rhythm disturbances]. Mazur NA Klin Med (Mosk); 1982 May; 60(5):68-72. PubMed ID: 7109520 [No Abstract] [Full Text] [Related]
4. [Combinations of anti-arrhythmia agents and the heart conduction system]. Pleskot M; Tilser P; Pidrman V Vnitr Lek; 1988 Jan; 34(1):23-30. PubMed ID: 3354214 [No Abstract] [Full Text] [Related]
5. [Euchronotropic and eubatmotropic effects of hexobendine. I. Introduction to its anti-arrhythmic action]. Martínez-Muñoz A Rev Esp Cardiol; 1969 Jan; 22(1):57-66. PubMed ID: 5799323 [No Abstract] [Full Text] [Related]
6. [Anti-arrhythmia agents]. Forfang K Tidsskr Nor Laegeforen; 1979 Jun; 99(17-18):891-4. PubMed ID: 473141 [No Abstract] [Full Text] [Related]
7. [Anti-arrhythmia agents. Effectiveness, lack of effectiveness and pro-arrhythmia effects]. Steinbeck G Internist (Berl); 1992 Oct; 33(10):663-9. PubMed ID: 1385349 [No Abstract] [Full Text] [Related]
8. The pharmacology of cardio-active agents. Hayes AH Cardiovasc Clin; 1972; 4(3):103-18. PubMed ID: 4130206 [No Abstract] [Full Text] [Related]
11. [Effect of anti-arrhythmia drugs on the heart conduction system]. Walczak F Kardiol Pol; 1992; 36(2):92-6. PubMed ID: 1583832 [No Abstract] [Full Text] [Related]
12. [Hemodynamic action of propafenon in patients with atherosclerotic coronary disease]. Lamounier EN; Martinez Filho EE; Herrmann JL; Guimarães RD; Portugal OP; Barcellini A Arq Bras Cardiol; 1979 Jul; 33(1):73-6. PubMed ID: 526178 [No Abstract] [Full Text] [Related]
13. [Comparison of the effects of disopyramide and hydroquinidine in animals]. Lisin N; Carlier J Arch Mal Coeur Vaiss; 1973 Oct; 66(10):1329-35. PubMed ID: 4207476 [No Abstract] [Full Text] [Related]
14. [The way of thinking about classification of antiarrhythmic drugs]. Sawanobori T Kokyu To Junkan; 1989 Dec; 37(12):1301-7. PubMed ID: 2616906 [No Abstract] [Full Text] [Related]
15. [Proposals for a new grouping of anti-arrhythmia agents (use of an electrophysiologic method for the direct study in man)]. Domenichelli B; Manzoli U; Feraco E; Schiavoni G Boll Soc Ital Cardiol; 1973; 18(9):877-85. PubMed ID: 4807173 [No Abstract] [Full Text] [Related]
16. [Antazolin(Antistina) in treatment of supraventricular tachycardia]. Mortensen E; Andersen M Ugeskr Laeger; 1974 Jun; 136(25):1393-4. PubMed ID: 4841115 [No Abstract] [Full Text] [Related]
17. [The proarrhythmia effects of anti-arrhythmia drugs]. Popescu P Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1988; 40(2):97-109. PubMed ID: 2908081 [No Abstract] [Full Text] [Related]
18. Shortcomings of the present classification system of anti-arrhythmic drugs. Weirich J; Antoni H Eur Heart J; 1992 Jun; 13(6):862-3. PubMed ID: 1320569 [No Abstract] [Full Text] [Related]
19. [Action of 17-monochloro-acetylajmaline, a new anti-arrhythmia drug, upon myocardial contractility]. Bardet J; Roudy G; Rocha P; Riguad M; Mathivat A; Bourdarias JP Ann Cardiol Angeiol (Paris); 1974; 23(6):539-44. PubMed ID: 4618072 [No Abstract] [Full Text] [Related]
20. [Antiarrhythmic agents. Receptor hypothesis explains mechanisms of action]. Bjørnstad H; Refsum H Tidsskr Nor Laegeforen; 1991 Oct; 111(26):3187-9. PubMed ID: 1658976 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]